Mechanisms of selective anticancer action of histone deacetylase inhibitors

Cell Cycle

Volumn 4, Issue 6, 2005, Pages 741-743

  Insinga, Alessandra ^a   Minucci, Saverio ^a,b   Pelicci, Pier Giuseppe ^a,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Apoptosis; Death receptors; Leukemia; Mouse model; Oncogenic fusion protein; p53

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; LIGAND; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLAST CELL; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; DEREGULATION; ENZYME MECHANISM; GENE EXPRESSION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 25144487124     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.6.1717     Document Type: Short Survey

References (25)

1. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-80.
2. Turner BM. Cellular memory and the histone code. Cell 2002; 111:285-91.
3. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999; 99:451-4.
4. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33:245-54.
5. Johnson CA, Turner BM. Histone deacetylases: Complex transducers of nuclear signals. Semin Cell Dev Biol 1999; 10:179-88.
6. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70:81-120.
7. Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001; 20:3110-5.
8. Phillips AC, Vousden KH. Acetyltransferases and tumour suppression. Breast Cancer Res 2000; 2:244-6.
9. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163-7.
10. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28.
11. Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer? Cancer Cell 2002; 2:349-50.
12. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, Pelicci PG. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 2000; 5:811-20.
13. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1:194-202.
14. Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287-99.
15. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 2003; 4:13-8.
16. Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: From target to clinical trials. Expert Opin Investig Drugs 2002; 11:1695-713.
17. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92:1210-6.
18. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, Pelicci PG. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391:815-8.
19. Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000; 5:821-30.
20. Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, Pruneri G, Viale G, Appella E, Pelicci P, Minucci S. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. Embo J 2004; 23:1144-54.
21. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108:153-64.
22. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7:680-6.
23. Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002; 2:139-48.
24. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10:66-75.
25. Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003; 2:1273-84.